Project Description
Under this model, the pharmacy will engage directly with AstraZeneca to procure AstraZeneca products. The supply of products will be fulfilled from AstraZeneca's warehouse, with the pharmacy assuming full responsibility for receipt and handling.
All distribution activities must strictly adhere to WHO Annex 5: Good Distribution Practices (GDP) for Pharmaceutical Products, ensuring the quality, safety, and integrity of products throughout the supply chain (refer to WHO guidelines).
KT Key Terms
Payment Terms
Financial arrangements will be determined based on the outcome of a comprehensive financial assessment.
Terms & Conditions
The relationship between AstraZeneca and the pharmacy will be governed by mutually agreed terms and conditions.
Compliance Requirement
Applications will only be considered if all required documentation and prerequisites are fully met. Failure to comply will result in exclusion from the program.
Selection Criteria
Registered and Licensed Accounts
- The pharmacy must be a licensed account in accordance with EDA requirements.
- A valid Commercial Register (CR) and Tax Card must be available.
- Compliance with EDA Track and Trace requirements once implemented, with full product traceability.
- Compliance with EDA requirements for handling pharmaceutical products, including ambient and cold chain temperature controls.
Financial Criteria
- Submission of audited financial statements for the last three (3) years.
- If incorporated for less than three years, provide all available audited financial statements since inception.
- AstraZeneca will conduct a creditworthiness assessment based on the submitted data.
- Based on the assessment outcome, AstraZeneca may require a financial guarantee.
- The pharmacy must successfully pass the credit assessment to proceed.
Automated System Availability
- The pharmacy must have an automated database system to track sales-in and sales-out data.
- Monthly sales reports must be submitted, including sales-in, sales-out, and stock levels.
- AstraZeneca may conduct physical stock counts for its products when required.
- No unjustified off-trend sales history is permitted.
- Any officially reported parallel trade cases of AstraZeneca products reported to EDA will result in exclusion.
Due Diligence
- The pharmacy must be registered and approved on the AstraZeneca 3PRM (Third Party Risk Management) portal.
- The 3PRM process ensures that third-party risks are identified and managed effectively and at an early stage.
Ready to Apply?
Incomplete applications or missing documentation will not be considered. Compliance with all requirements is mandatory for participation in the program.